Share Name Share Symbol Market Type Share ISIN Share Description
Instem Plc LSE:INS London Ordinary Share GB00B3TQCK30 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 745.00 1,109 08:00:00
Bid Price Offer Price High Price Low Price Open Price
740.00 750.00 745.00 745.00 745.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 25.72 -0.90 -5.70 156
Last Trade Time Trade Type Trade Size Trade Price Currency
14:55:53 O 233 749.00 GBX

Instem (INS) Latest News

More Instem News
Instem Investors    Instem Takeover Rumours

Instem (INS) Discussions and Chat

Instem Forums and Chat

Date Time Title Posts
09/6/202120:22Instem Life216
26/11/201916:54chevy retail 2501
02/1/201222:19INSULTS...what is the best one ?11
05/1/201016:26Newbie to BB ! any viewpoint30
13/4/200814:52INTERNATIONAL NUCLEAR SOLUTIONS double your money132

Add a New Thread

Instem (INS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Instem trades in real-time

Instem (INS) Top Chat Posts

Instem Daily Update: Instem Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker INS. The last closing price for Instem was 745p.
Instem Plc has a 4 week average price of 720p and a 12 week average price of 675p.
The 1 year high share price is 800p while the 1 year low share price is currently 425p.
There are currently 20,873,829 shares in issue and the average daily traded volume is 221,250 shares. The market capitalisation of Instem Plc is £155,510,026.05.
jombaston: I don't think there are any in the UK, not listed anyway. Phil Reason mentioned a company called Cetara which is NASDAQ listed. They have a $3.9bn mkt cap which is 14x their projected 2021 sales. Instem mkt cap of £133m is 2.7x 2021E revenue. EV/EBITDA Cetara is 38.2x whereas INS is 14.4x. Their products are more complements than substitutes even though they operate in the same field and obviously you would expect NASDAQ companies to be rated more highly because, er, well, they just are!
mw8156: buy price 577 sell price 580 this morning albeit for only 500 maker short of stock?
p1nkfish: Back near placing price too.
p1nkfish: Interesting statement. "The 'working from home' impact of COVID-19 has increased the number of conversations that the Group is holding with target principals." The ability to scale with the SaaS model is attractive. A global platform to promote new capabilities and services from & the market is so fragmented there should be rich pickings to put on the platform. I have no idea if this will fall back the placing price or below but the statement "The Placing was significantly oversubscribed" makes me think not. The disappointed could buy in the market not much over the placement price.
p1nkfish: I can't see this virus being negative for INS. What am I missing?
mw8156: large volume, by standards today and yesterday with rising share price, ought to be a bullish signal but have no idea what's going on in the background.
tomps2: Here's the Instem investor presentation by Phil Reason, CEO. Given at the piworld-Progressive Equity Research event in September. Phil was over for the H1 19 results, (normally he's in the US). A very comprehensive overview of the different parts of the business, and a positive outlook. Https://
2niffy: Rights issue very unlikely. Management incentivised by share price. They own 16% ish of company at 102p.Rights issue dilutes them, loss of control.
slopsjon2: Trading Update Results in-line with management expectations SEND contract value in H1 2018 exceeds that for the entire FY2017 Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces a trading update for the six months to 30 June 2018 (the "Period"). Financial Highlights Trading for the Period was in-line with management expectations. Net cash as at 30 June 2018 was GBP3.7m (30 June 2017; GBP1.2m). Operational Highlights There were positive contributions in most areas, with several significant new client wins in addition to existing customers extending and expanding their adoption of Instem's products and services. Investment in Instem's early phase clinical product, Alphadas, was increased with a focus on current client needs and recognising that the enhancements will have wider market appeal going forward. Importantly, the business continued to expand its SaaS delivery model for accessing its solutions via the Instem Cloud with both Provantis(R) and Samarind RMS being deployed via Software-as-a-Service by additional multinational corporations. SEND Market Update The Regulatory Solutions business performed particularly strongly during the period following the latest FDA mandate of the Standard for the Exchange of Non-clinical Data ("SEND"). Increasing Number of Contract Wins Orders for the Company's SEND software solutions and technology-enabled SEND out-sourced services over the period have increased year-on-year with 103 orders won during the six-month period ended 30 June 2018, compared to 47 and 65 for the first and second six-month periods of 2017 respectively. Importantly, more SEND out-sourced services deals were closed in the first half of 2018 than for the entire 2017 financial year. These contract wins will increasingly impact overall Group revenues in H2 and beyond in line with recruitment of the necessary services personnel, which has been ongoing throughout 2018. These new orders came from 50 unique clients during the period, compared with 32 for the equivalent period last year and the Company continues to win the overwhelming majority of all business quoted for. All of Instem's study conversions are performed on a secure, hosted and validated SEND services platform, which is available and supported 24/7 utilising Instem's submit(TM) SEND software suite. This is the same submit(TM) software that is in production use at pharma and contract research organisations worldwide. Increasing Contract Value The total contracted value of SEND-related new business for the current period increased approximately 190% over the corresponding period last year with outsourced services orders particularly strong. Increasing Pipeline The Company continues to believe that this rapid growth has been largely driven by the IND ('Investigational New Drug') legislation from the FDA, which mandated that studies started after 17 December 2017 and included in IND regulatory submissions must use the electronic SEND format. Future demand appears to be similarly robust and the Company has a strong SEND new business pipeline for both technology and service related sales, with both the number and value of SEND contracts expected to increase in the second half of 2018 and expected to be significantly ahead of last year. Outlook The further shift towards a SaaS based revenue model, combined with increasingly material recurring outsourced services revenue, will see a continued improvement of earnings visibility. This helps position the Company strongly to meet management's full year expectations. Phil Reason, CEO of Instem plc, commented: "The financial year has started well and we are confident further new business, the delivery of recent contract wins and strong operational management will ensure we meet our expectations for the full year."
Instem share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210729 19:54:52